Apellis Pharma

$65.46 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Apellis Pharma

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.

Stock Analysis

last close $65.46
1-mo return 40.2%
3-mo return 86.7%
avg daily vol. 1.42M
52-week high 67.74
52-week low 27.5
market cap. $6.7B
forward pe -
annual div. -
roe -662%
ltg forecast -
dividend yield -
annual rev. $97M
inst own. 88.2%
baraka

Subscribe now for daily local and international financial news

Subscribe